Azithromycin Is not Associated With Qt Prolongation In Patients Hospitalized With Community Acquired Pneumonia

Abstract

e36 Volume 37 Number 8S Previous studies using a liver damage model treated with the immunemodulator metallo-peptide (IMMP) showed lessening in the degree of inflammation. Therefore, this study was set up to evaluate the anti-inflammatory effect of IMMP in obese Zucker fa/fa rats. We used Zucker-Lepr fa/fa and Zucker-Lean in this protocol. Material and Methods: The groups received IMMP 50 ng/kg by i.p., 3 times per week for 8 weeks. Blood samples were collected by cardiac puncture and the serum was preserved at −80°C until analysis; the liver was excised and preserved in formaldehyde 4%. Analyses were performed to determine cytokine, insulin, glucose, triglyceride and cholesterol levels in serum, and histological analysis was also performed. Results:: IMMP treatment of obese rats resulted in decreased levels of proinflammatory cytokines (leptin, IL-6, IL-1β , IFN-γ ) and a chemokine (MCP-1), and increased levels of anti-inflammatory adipokine (adiponectin). In addition, treatment decreased the damage and hepatic steatosis generated in the tissue of obese rats and avoids changes in thymus and spleen in the same animals. Conclusions: The IMMP exerted an anti-inflammatory effect in obese rats and therefore may be an effective and safe therapeutic alternative in the treatment of metabolic syndrome.